title: Extraocular muscle cysticercosis: clinical features and management outcome.
abstract: BACKGROUND
  Extraocular muscle cysticercosis is rare and can be classified based on the stage of evolution as viable, degenerating, and inactive. A tailored approach to therapy using a combination of albendazole and steroids has been proposed. In this study, we have evaluated the clinical features and response of "viable" extraocular muscle cysticercosis to a tailored therapy with oral albendazole and steroids.
  
  
  METHODS
  A retrospective review of 32 patients with viable extraocular muscle cysticercosis was performed over a 3-year period. Ultrasound examination was performed at 3 weeks and 6 weeks for resolution of the cyst and clinical signs following treatment with oral albendazole and prednisolone. The clinical presentation, ocular alignment, motility restriction, and ultrasound examination details were recorded on serial visits.
  
  
  RESULTS
  The mean age was 19.5 years. The most common presenting signs included limitation of ocular motility in 75%, conjunctival mass in 37.5%, diplopia in 28.1%, and proptosis in 28.1% of the patients, respectively. Ocular alignment evaluation revealed esotropia in 3.1%, exotropia in 12.5%, and hypertropia in 6.25%. Restriction of abduction and abduction in elevation was present in two patients each. The average time for complete resolution was 65.9 days. All the patients had resolution, except four, who had residual motility limitation but were asymptomatic.
  
  
  CONCLUSIONS
  Combination therapy with oral albendazole and steroids is effective in the management of viable extraocular muscle cysticercosis. However, residual motility restriction may persist despite treatment.
authors.affiliation: Pediatric Ophthalmology and Strabismus, LVPrasad Eye Institute, Hyderabad, India. rameshmurthy@lvpei.org
authors.forename: Ramesh
authors.initials: R
authors.lastname: Murthy
authors.forename: Monica
authors.initials: M
authors.lastname: Samant
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D015766:Albendazole / Q000008:administration & dosage / Q000627:therapeutic use; D000923:Anticestodal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003229:Conjunctival Diseases / Q000469:parasitology; D003551:Cysticercosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D004172:Diplopia / Q000469:parasitology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005094:Exophthalmos / Q000469:parasitology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009801:Oculomotor Muscles / Q000187:drug effects / Q000469:parasitology* / Q000503:physiopathology; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D013285:Strabismus / Q000469:parasitology; D016896:Treatment Outcome; D014463:Ultrasonography; D055815:Young Adult
chemical_list: D000923:Anticestodal Agents; D011239:Prednisolone; D015766:Albendazole